Show simple item record

dc.contributor.authorSocinski, M
dc.contributor.authorObasaju, C
dc.contributor.authorGandara, D
dc.contributor.authorHirsch, F
dc.contributor.authorBonomi, P
dc.contributor.authorBunn, P
dc.contributor.authorKim, E
dc.contributor.authorLanger, C
dc.contributor.authorNatale, R
dc.contributor.authorNovello, S
dc.contributor.authorPaz-Ares, L
dc.contributor.authorPérol, M
dc.contributor.authorReck, M
dc.contributor.authorRamalingam, S
dc.contributor.authorReynolds, C
dc.contributor.authorSpigel, D
dc.contributor.authorStinchcombe, T
dc.contributor.authorWakelee, H
dc.contributor.authorMayo, C
dc.contributor.authorThatcher, Nick
dc.date.accessioned2016-08-10T10:06:00Z
dc.date.available2016-08-10T10:06:00Z
dc.date.issued2016-06-11
dc.identifier.citationClinicopathologic Features of Advanced Squamous NSCLC. 2016: J Thorac Oncolen
dc.identifier.issn1556-1380
dc.identifier.pmid27296106
dc.identifier.doi10.1016/j.jtho.2016.05.024
dc.identifier.urihttp://hdl.handle.net/10541/618176
dc.description.abstractLung cancer remains the leading cause of cancer-related death worldwide. NSCLC accounts for more than 85% of all lung cancers, and the prognosis for advanced-stage disease is typically poor. In recent years, the importance of histologic subtypes of NSCLC has been recognized, and the distinction between squamous and other NSCLC histologic subtypes is now critical to patient management. Squamous cell lung cancer (sqCLC) represents approximately 25% to 30% of NSCLC. The prognosis for patients with advanced NSCLC is poorer for those with sqCLC than for those with adenocarcinoma. This is partly due to a number of clinical characteristics that distinguish sqCLC from other NSCLC histologic subtypes, such as smoking history, comorbid diseases, age, and molecular profile. Together, these factors make sqCLC an especially challenging disease to manage. Herein, we review some of the key clinicopathologic features of sqCLC. Understanding these features to optimally address many of the unique therapeutic challenges of this disease is likely to be central to ultimately improving outcomes for patients with squamous NSCLC.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of thoracic oncology : official publication of the International Association for the Study of Lung Canceren
dc.titleClinicopathologic Features of Advanced Squamous NSCLC.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, University of Pittsburgh Medical Center, PA, USAen
dc.identifier.journalJournal of Thoracic Oncologyen
html.description.abstractLung cancer remains the leading cause of cancer-related death worldwide. NSCLC accounts for more than 85% of all lung cancers, and the prognosis for advanced-stage disease is typically poor. In recent years, the importance of histologic subtypes of NSCLC has been recognized, and the distinction between squamous and other NSCLC histologic subtypes is now critical to patient management. Squamous cell lung cancer (sqCLC) represents approximately 25% to 30% of NSCLC. The prognosis for patients with advanced NSCLC is poorer for those with sqCLC than for those with adenocarcinoma. This is partly due to a number of clinical characteristics that distinguish sqCLC from other NSCLC histologic subtypes, such as smoking history, comorbid diseases, age, and molecular profile. Together, these factors make sqCLC an especially challenging disease to manage. Herein, we review some of the key clinicopathologic features of sqCLC. Understanding these features to optimally address many of the unique therapeutic challenges of this disease is likely to be central to ultimately improving outcomes for patients with squamous NSCLC.


Files in this item

This item appears in the following Collection(s)

Show simple item record